Pluristem Fast Forwards Placental Cell Therapy Into US-EU Pivotal Trial
Off-the-shelf placental cell therapy for peripheral artery disease will move from Phase I to registration stage study in US and Europe in early 2017, following “positive feedback” from FDA.
You may also be interested in...
Pluristem Therapeutics Chairman and CEO Zami Aberman explains how stem cell therapy will shape the industry, in a recent interview at the Biotech Showcase.
Companies developing 'advanced' treatments such as cell therapies face many of the same challenges in getting their innovative products to market, yet the attitudes of management towards the various hurdles differs quite significantly, Scrip found at Alliance for Regenerative Medicine's third annual 'European Advanced Therapies Investor Day' on Nov. 12.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.